ARCTICZYMES Aktie

 

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Tromsø, Norway, 14 August 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported results for the second quarter and first half of 2026. Second-quarter sales revenue rose 19% year-on-year to NOK 31.9 million, or 29% at constant exchange rates (CER), while EBITDA increased 90% to NOK 7.4 million. For the first half, sales revenue grew 27% to NOK 63.7 million (39% CER) and EBITDA reached NOK 9.0 million, against break-even in the same period last year. The defining feature of the half year is the conversion of growth into earnings. Sales rose 27% while operating expenses increased 12%,...

The Company will host a virtual Q2 and 6M 2026 presentation for investors, analysts and media at 08:30 CET on Friday, 14 August, 2026. The presentation will be given by CEO, Michael Akoh, CCO, Paul Blackburn and CFO, Børge Sørvoll. The presentation can be followed as a live webcast from Hegnar TV on https://qcnl.tv/p/urFHx-Z6HLY1rgjyT4D44Q or www.arcticzymes.com. It will be possible to post questions through the webcast console. The report for Q2 and 6M 2026 will be available on www.newsweb.no and on the company's homepage www.arcticzymes.com from 07.00 CET on Friday, 14 August, 2026....

Tromsø, Norway – 28 May 2026 – ArcticZymes Technologies ASA (OSE: AZT) today announced that, following approval at its Annual General Meeting, Dr. Hanna Pirita Lesch has been elected to the Company's Board of Directors. Dr. Frank Mathias has been re-elected as Chair, and Petter Dragesund has been re-elected as a Board member. Sharon Brownlow steps down from the Board after a period of valued service. The appointment directly supports the execution of ArcticZymes' strategy: diversifying into RNA through the build-out of a dedicated RNA enzyme portfolio, while continuing to strengthen the...

Tromsø, Norway - 28[th] April 2026 – ArcticZymes Technologies (Ticker: “AZT”)  announced its participation as an associated partner in the CAARE (Consortium for Advanced Analytical and Recovery Engineering) project, alongside an expansion of its ongoing research collaboration with the Austrian Centre of Industrial Biotechnology (acib), supported by additional funding through the COMET program. Together, these developments reinforce ArcticZymes' commitment to advancing downstream processing solutions for bionanoparticles, including viral vectors used in gene therapy, vaccines, and oncology...

Stockholm, 6 March 2026: ArcticZymes Technologies ASA (OSE: “AZT”) today hosts its Capital Markets Day 2026 in Stockholm, outlining how the Company is scaling a diversified enzyme platform designed to deliver sustainable growth and long-term value creation. Building on more than 30 years of enzyme expertise, ArcticZymes is positioned to benefit from increasing demand for high-performance enzymes used in molecular diagnostics, research and advanced biomanufacturing. “ArcticZymes is entering its next phase of growth. By strengthening our commercial engine, expanding our enzyme portfolio and...

ArcticZymes Technologies ASA (OSE: "AZT") is pleased to invite investors, analysts, media and other stakeholders to its upcoming Capital Markets Day. The objective of the day is to provide clearer insight into ArcticZymes' position, ambitions, strategic direction and long‑term value creation framework. Date: 6 March 2026 Venue: Smålandsgatan 17, Stockholm (Sweden) / virtually (details below) Time: Doors open at 08:30 Preliminary agenda: · 0830-0900: Registration and coffee · 0900-0915: Introduction · 0915-1200: Capital Markets Day & Q&A · 1200-1230: Lunch and investor...

Tromsø, Norway, February 12, 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported financial results for the fourth quarter and full year 2025, reflecting accelerating sales growth, improved operating leverage and continued penetration in its core business segments. Following a return to growth in 2025, the Company enters 2026 with strengthened commercial momentum and a robust balance sheet. Q4 2025 Highlights · Total revenue: NOK 34.7 million (Q4 2024: NOK 26.4 million), +31% year-on-year · Sales revenue: NOK 34.1 million (Q4 2024: NOK 24.5 million), +39% year-on-year ·...

ArcticZymes Technologies ASA invites investors, analysts and other stakeholders to its Capital Markets Day on 6 March 2026, 09:00–12:00 CET (registration and coffee from 08:30). The event will take place at Nordea's offices, Smålandsgatan 17, Stockholm, Sweden but can also be joined virtually.  Building a Scalable Enzyme Platform  At the Capital Markets Day, management will present how ArcticZymes has completed its commercial transformation and is now focused on scaling its enzyme platform across high-growth biomanufacturing and molecular tool markets.  The session will address:...

The Company will host a virtual Q4 and 12M 2025 presentation for investors, analysts and media at 10:00 CET on Thursday, 12 February, 2026. The presentation will be given by CEO, Michael Akoh, CCO, Paul Blackburn and CFO, Børge Sørvoll. The presentation can be followed as a live webcast from Hegnar TV on https://qcnl.tv/p/XRgPIoZrlRfhnjAmevVbeQ  or www.arcticzymes.com. It will be possible to post questions through the webcast console. The company is also pleased to announce it will host a Capital Markets Day Friday 6th March from 0900-1200, in Stockholm. More information will be...

Tromsø, Norway, November 28th, 2025 - Reference is made to the stock exchange announcement published by ArcticZymes Technologies ASA (the "Company", OSE: AZT) on 25 November 2025 announcing the initiation of a share buyback program pursuant to the authorization granted by the Annual General Meeting held on 27 May 2025. The share buyback program has now been completed. From and including 25 November 2025 to and including 28 November 2025, the Company has purchased a total of 31,365 own shares at an average price of NOK 22.5037 per share. Please see the attached table for further details....

(Tromsø/Oslo, 25 November 2025) ArcticZymes Technologies ASA (OSE:AZT) will today present at DNB Carnegie's Nordic Healthcare Conference 2025 in Oslo. Estimated start of the presentation will be at 09.25 CET Speaker will be CEO, Michael Akoh Please find the presentation enclosed For further information: Børge Sørvoll CFO +47 950 90 187 ir@arcticzymes.com...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Tromsø, Norway, November 6, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the third quarter of 2025, reporting strong topline growth and solid operational performance. Total revenues reached NOK 29.8 million, an increase of 24% year-over-year, driven by robust performance across both Biomanufacturing and Molecular Tools segments. A significant milestone following the end of the quarter was the signing of an exclusive European partnership agreement with Brenntag, expanding ArcticZymes' reach in the biomanufacturing market for advanced therapies. Key...

MUEHLHEIM (dpa-AFX) - Brenntag SE (BNTGF.PK), Wednesday announced an exclusive distribution agreement with ArcticZymes AS on the salt-active nucleases - SAN HQ, SAN-HQ GMP, M-SAN HQ, M-SAN HQ GMP.......

Tromsø, Norway, August 14, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the second quarter of 2025, highlighting progress in the Company's commercial transformation. Total revenues reached NOK 28.9 million, up 5% year-over-year, led by strong 52% growth in the Biomanufacturing segment which contributed NOK 18.1 million. The quarter also marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a product developed in direct response to customer needs. M-SAN HQ GMP enables broader integration into viral vector manufacturing and...